avatrombopag (higher baseline platelet count)

DRUG2 trials

Sponsors

Eisai Inc.

Conditions

Thrombocytopenia Associated With Liver Disease

Phase 3

Treatment of Thrombocytopenia in Patients With Chronic Liver DiseaseUndergoing an Elective Procedure

CompletedNCT01972529

Eisai Inc.Thrombocytopenia Associated With Liver Disease

Start: 2014-02-28End: 2017-02-27Updated: 2018-02-27

Treatment of Thrombocytopenia in Patients With Chronic Liver Disease Undergoing an Elective Procedure

CompletedNCT01976104

Eisai Inc.Thrombocytopenia Associated With Liver Disease

Start: 2013-11-30End: 2017-02-21Updated: 2018-02-27

Related Papers

Avatrombopag, an Alternate Treatment Option to Reduce Platelet Transfusions in Patients with Thrombocytopenia and Chronic Liver Disease-Integrated Analyses of 2 Phase 3 Studies

International Journal of Hepatology2020-01-2519 citations

Avatrombopag Before Procedures Reduces Need for Platelet Transfusion in Patients With Chronic Liver Disease and Thrombocytopenia.

2018-05-17170 citations

Superiority of Avatrombopag to Placebo in Increasing Platelet Counts in Patients with Chronic Liver Disease-Associated Thrombocytopenia Undergoing Scheduled Procedures: Results from 2, Phase 3 Randomized Studies

Blood2017-12-076 citations